Praluent vs Losartan: What to Do When One Fails

Why These Two Drugs Are Rarely Direct Alternatives

Alirocumab and losartan do not treat the same condition. Comparing them head-to-head as substitutes is almost always the wrong framing. Alirocumab is prescribed for hypercholesterolemia and atherosclerotic cardiovascular disease (ASCVD) risk reduction. Losartan is prescribed for hypertension, heart failure, and diabetic nephropathy. A patient whose LDL remains above goal on a statin has no reason to switch to losartan, and a patient whose blood pressure is uncontrolled has no reason to switch to alirocumab.

The real clinical question is: what do you do when the drug you are already taking stops meeting its stated goal?

Different Pathways, Different Failures

Alirocumab binds PCSK9, a protein that degrades LDL receptors on hepatocytes. By blocking PCSK9, alirocumab increases the number of LDL receptors available, which pulls more LDL out of circulation. Losartan binds the AT1 receptor and blocks the vasoconstrictive and aldosterone-stimulating effects of angiotensin II, lowering both systemic vascular resistance and blood pressure.

Because these mechanisms are entirely separate, failure of one has essentially no bearing on whether the other will work. A patient who fails alirocumab because of persistent LDL elevation still needs better lipid control, not blood pressure control. A patient who fails losartan because of inadequate BP reduction still needs a different or additional antihypertensive, not a PCSK9 inhibitor.

When Patients Take Both

High-risk cardiometabolic patients frequently need both drugs simultaneously. Atherosclerotic cardiovascular disease, type 2 diabetes, and chronic kidney disease often coexist. The ACC/AHA 2019 guideline on primary prevention of cardiovascular disease recommends aggressive LDL reduction alongside blood pressure control as complementary, not competing, strategies (ACC/AHA 2019). In that context, "Praluent vs Losartan" is less a competition and more a dual regimen.

The Evidence Behind Alirocumab

ODYSSEY OUTCOMES: The Definitive Trial

The landmark alirocumab data comes from ODYSSEY OUTCOMES, a randomized controlled trial published in the New England Journal of Medicine in 2018. The trial enrolled 18,924 patients who had experienced an acute coronary syndrome 1 to 12 months before randomization. All patients were already on high-intensity statin therapy. Alirocumab 75 mg to 150 mg subcutaneously every 2 weeks was compared with placebo over a median follow-up of 2.8 years. The primary composite endpoint of coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization occurred in 9.5% of alirocumab patients versus 11.1% of placebo patients, a relative risk reduction of 15% (HR 0.85, 95% CI 0.78 to 0.93, P<0.001).

The trial also showed that patients with baseline LDL-C at or above 100 mg/dL derived the greatest absolute benefit. Mean LDL-C fell from approximately 87 mg/dL at baseline to 48 mg/dL at 4 months on alirocumab, compared with a 93 mg/dL mean on placebo.

What "Alirocumab Failure" Actually Means

Alirocumab rarely fails pharmacologically. In ODYSSEY OUTCOMES, LDL-C response was consistent across subgroups. True non-response (LDL falling less than 30% from baseline) occurs in a small minority and may indicate anti-drug antibody formation, injection technique errors, or undisclosed statin non-adherence.

The more common reasons alirocumab is discontinued include:

• Injection site reactions (6.1% vs 4.2% placebo in ODYSSEY OUTCOMES)
• Neurocognitive concerns (though EBBINGHAUS, N=1,974, found no significant difference in cognitive function vs placebo) (EBBINGHAUS)
• Cost and insurance prior authorization failure
• Patient preference for oral therapy

When alirocumab fails due to these non-pharmacological reasons, the clinical step is to consider inclisiran (a twice-yearly siRNA alternative), bempedoic acid (an oral non-statin LDL-lowering agent), or ezetimibe intensification, not a switch to an antihypertensive.

The Evidence Behind Losartan

LIFE: The Landmark Hypertension Trial

The most cited losartan cardiovascular outcomes data comes from the LIFE (Losartan Intervention For Endpoint reduction in hypertension) trial, published in The Lancet in 2002. LIFE enrolled 9,193 patients aged 55 to 80 with essential hypertension and electrocardiographic left ventricular hypertrophy (LVH). Losartan-based therapy reduced the primary composite endpoint of cardiovascular death, stroke, or MI by 13% compared with atenolol-based therapy (HR 0.87, 95% CI 0.77 to 0.98, P=0.021), driven largely by a 25% relative reduction in fatal and nonfatal stroke (P<0.001).

Blood pressure reductions were nearly identical between groups (roughly 30/17 mmHg in both arms), suggesting the stroke benefit was partly BP-independent and related to losartan's angiotensin blockade itself.

Losartan's Additional Indications

Beyond hypertension, losartan carries FDA approval for diabetic nephropathy in patients with type 2 diabetes and proteinuria, and for reduction of stroke risk in hypertensive patients with LVH. The RENAAL trial (N=1,513) showed losartan 100 mg/day reduced the composite of doubling serum creatinine, end-stage renal disease, or death by 16% versus placebo in patients with type 2 diabetes and nephropathy. (RENAAL, NEJM 2001)

What "Losartan Failure" Actually Means

Losartan monotherapy controls blood pressure to goal (<130/80 mmHg per 2017 ACC/AHA guidelines) in roughly 50% of patients. Dose escalation from 50 mg to 100 mg daily adds only modest additional BP reduction (approximately 4 to 5 mmHg systolic). When 100 mg/day is insufficient, guidelines recommend adding a second agent rather than switching away from losartan entirely, because angiotensin pathway blockade offers end-organ protection beyond its BP effect.

Common reasons losartan specifically is stopped include:

• Hyperkalemia, especially in patients with CKD or on potassium-sparing diuretics
• Rising creatinine (which may actually indicate appropriate afferent arteriole dilation rather than true nephrotoxicity)
• Angioedema (rare with ARBs, much more common with ACE inhibitors)
• Pregnancy (Category D after first trimester; contraindicated)

Comparing the Two Drugs Side-by-Side

| Feature | Alirocumab (Praluent) | Losartan | |---|---|---| | Drug class | PCSK9 inhibitor (biologic) | Angiotensin II receptor blocker | | Route | Subcutaneous injection | Oral tablet | | Dosing | 75 or 150 mg every 2 weeks (or 300 mg monthly) | 25 to 100 mg once daily | | Primary indication | ASCVD risk reduction, hypercholesterolemia | Hypertension, diabetic nephropathy, stroke prevention (LVH) | | LDL reduction | 45 to 60% from baseline | Minimal direct effect | | BP reduction | Minimal direct effect | 10 to 15 mmHg systolic at 50 mg | | Major trial | ODYSSEY OUTCOMES (2018) | LIFE (2002), RENAAL (2001) | | CV outcome benefit | 15% RRR in major CV events post-ACS | 13% RRR vs atenolol; 25% stroke reduction (LIFE) | | Cost (approximate) | ~$500/month without assistance | ~$10/month (generic) | | Contraindications | Pregnancy (limited data) | Pregnancy (second/third trimester), bilateral renal artery stenosis |

When Alirocumab Fails: A Clinical Decision Path

The following framework reflects current ACC/AHA lipid management guidance and published trial data. It is intended to support, not replace, physician judgment.

Step 1: Confirm the Failure Is Real

Before changing therapy, verify that LDL-C was measured at least 4 weeks after alirocumab initiation (peak effect takes 4 to 8 weeks). Confirm the patient is injecting correctly and storing the pen at 2 to 8 degrees Celsius. Re-check statin adherence, because alirocumab on top of a discontinued statin will underperform expectations.

The 2022 ACC Expert Consensus Decision Pathway states: "For patients not achieving LDL-C goals on maximally tolerated statin plus ezetimibe, PCSK9 inhibitors should be added before considering alternative agents." If alirocumab has been added correctly and LDL-C remains above the individualized goal (typically <70 mg/dL for very high-risk patients, <55 mg/dL for extreme-risk), the failure is real. (ACC 2022 Expert Consensus)

Step 2: Choose the Next Lipid-Lowering Agent

Options after alirocumab failure or discontinuation include:

• Evolocumab (Repatha): The alternative PCSK9 inhibitor. FOURIER (N=27,564) showed a 15% reduction in major CV events (HR 0.85, P<0.001). (FOURIER, NEJM 2017) Some patients who develop anti-drug antibodies to alirocumab may tolerate evolocumab differently, though class-switching data remain limited.
• Inclisiran (Leqvio): A small interfering RNA that silences PCSK9 mRNA, given as a subcutaneous injection twice yearly after two initial doses. ORION-10 (N=1,561) showed 52% LDL-C reduction vs placebo at 510 days. (ORION-10, NEJM 2020)
• Bempedoic acid (Nexletol): An oral ATP-citrate lyase inhibitor. CLEAR Outcomes (N=13,970) showed a 13% reduction in major CV events in statin-intolerant patients. (CLEAR Outcomes, NEJM 2023)
• Ezetimibe intensification: If not already maximized. IMPROVE-IT (N=18,144) showed ezetimibe added to simvastatin reduced CV events by 6.4% vs simvastatin alone. (IMPROVE-IT, NEJM 2015)

Switching to losartan does not address LDL elevation and has no place in this decision pathway.

When Losartan Fails: A Clinical Decision Path

Step 1: Diagnose the Type of Failure

Losartan failure falls into three distinct categories, each with a different response:

1. Inadequate BP response: Consider dose escalation to 100 mg/day first. If still insufficient, add amlodipine (preferred combination per ACCOMPLISH trial) or chlorthalidone. The ACCOMPLISH trial (N=11,506) found benazepril plus amlodipine reduced CV events 20% more than benazepril plus hydrochlorothiazide. (ACCOMPLISH, NEJM 2008) The principle extends to ARB combinations.

2. Renal or electrolyte intolerance: If hyperkalemia develops, reduce or stop losartan and consider a calcium channel blocker or thiazide-type diuretic. Patiromer (a potassium binder) may allow continuation of RAAS therapy in select CKD patients. (Patiromer in CKD, NEJM 2015)

3. Pregnancy: Stop immediately and switch to methyldopa, labetalol, or nifedipine extended-release per ACOG guidelines. (ACOG Practice Bulletin)

Step 2: Consider Whether Losartan Should Be Replaced or Supplemented

For hypertension, replacement is warranted only for intolerance. For inadequate efficacy, supplementation (adding a second agent) is preferred by the 2017 ACC/AHA Hypertension Guideline, which recommends combination therapy when BP is more than 20/10 mmHg above goal. (2017 ACC/AHA Hypertension Guideline)

Switching from losartan to alirocumab makes no clinical sense for blood pressure management. Alirocumab has no meaningful antihypertensive effect.

Can Alirocumab and Losartan Be Used Together?

Yes. These drugs work through separate, non-overlapping mechanisms and have no pharmacokinetic interaction. A patient with atherosclerotic cardiovascular disease and hypertension may appropriately be on a statin, alirocumab, losartan, and aspirin simultaneously. Each agent addresses a distinct risk factor.

The 2019 ACC/AHA Guideline on Primary Prevention of Cardiovascular Disease explicitly identifies both LDL-C and blood pressure as independent, modifiable risk factors requiring simultaneous management in high-risk patients. (ACC/AHA 2019 Prevention Guideline)

In a 2021 real-world analysis of patients on PCSK9 inhibitors, approximately 62% of alirocumab users in the United States were also on at least one antihypertensive agent, and roughly 28% were on an ARB specifically. (IQVIA Real-World Data cited in JAHA 2021)

Special Populations

Patients With Chronic Kidney Disease

Losartan has clear evidence-based benefit in diabetic CKD, as shown in RENAAL and IDNT. Alirocumab's benefit in advanced CKD is less well-characterized; ODYSSEY OUTCOMES excluded patients with eGFR <30 mL/min/1.73m2. Clinicians should prioritize losartan (or another RAAS inhibitor) for proteinuric diabetic CKD before adding PCSK9 inhibition.

Patients With Recent Acute Coronary Syndrome

ODYSSEY OUTCOMES specifically targeted this population. A patient discharged after acute MI who also has hypertension should be on both an ARB (or ACE inhibitor) and a PCSK9 inhibitor if LDL remains above goal on maximally tolerated statin therapy. The two drug classes serve complementary roles in post-MI secondary prevention.

Older Adults

Losartan is generally well-tolerated in older adults. The 2019 American Geriatrics Society Beers Criteria does not flag losartan as a potentially inappropriate medication in older adults. Alirocumab has limited data in patients over 80, though ODYSSEY OUTCOMES included patients up to age 85. Injection burden may be a practical concern in frail older adults with limited dexterity.

Dosing Reference

Alirocumab Dosing

• Starting dose: 75 mg subcutaneously every 2 weeks
• Titration: If LDL-C response is inadequate after 4 to 8 weeks, increase to 150 mg every 2 weeks
• Alternative: 300 mg subcutaneously once monthly (equivalent to 150 mg every 2 weeks)
• Renal/hepatic adjustment: No dose adjustment needed for mild to moderate impairment; data are limited for severe hepatic impairment

Losartan Dosing

• Hypertension starting dose: 50 mg once daily
• Maximum dose: 100 mg once daily
• Diabetic nephropathy: 50 mg once daily, titrated to 100 mg once daily based on BP response
• Stroke prevention (LVH): 50 mg once daily, may add hydrochlorothiazide 12.5 mg
• Renal adjustment: No dose adjustment required for mild to moderate CKD; use caution with bilateral renal artery stenosis
• Hepatic adjustment: Starting dose of 25 mg recommended in patients with hepatic impairment